Bayer’s Kidney Disease Drug Kerendia Approved in China

Bayer has just earned approval in China for the use of its drug Kerendia (finerenone) in the treatment of chronic kidney disease (CKD) associated with type 2 diabetes. Results from the FIDELIO-DKD showed that adding Kerendia to existing aggressive treatment plans reduced disease progression and death by 18% and cardiovascular outcomes by 14%. The decision is the latest of a series of regulatory wins for the drug, recently gaining approval in the US, Japan, and the EU.

According to Phil Taylor, “Bayer’s position has been that Kerendia is not so much in direct competition with the SGLT2s, but rather is a complementary therapy that can be used alongside them to improve the treatment options available. In its favour too is that it does not work as a diabetes medicine like the SGLT2s, so patients on insulin do not need to adjust their dose if Kerendia is added in to their treatment.”

To read more, click here.

(Source: Pharma Phorum, July 1st, 2022)